XML 57 R34.htm IDEA: XBRL DOCUMENT v3.25.2
Acquisitions and License Agreements (Additional Information) (Details) - USD ($)
3 Months Ended 12 Months Ended
Feb. 22, 2025
Jun. 14, 2022
May 31, 2022
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Feb. 28, 2025
Business Acquisition [Line Items]                
Royalty expenses       $ 100,000 $ 0 $ 300,000 $ 26,000  
Payment to acquire license       0   0    
Accrued Royalty Payables       100,000   100,000 5,000  
Tlido Rest Of World License Agreement [Member]                
Business Acquisition [Line Items]                
Percentage of Lidocaine Topical System 1.80%              
Aggregate Payment Of Company $ 200,000              
Gloperba Rest of World License Agreement [Member]                
Business Acquisition [Line Items]                
Revenue, Remaining Performance Obligation, Percentage               50.00%
Elyxyb Rest of World License Agreement [Member]                
Business Acquisition [Line Items]                
Revenue, Remaining Performance Obligation, Percentage               50.00%
Patents [Member] | Sorrento [Member]                
Business Acquisition [Line Items]                
Payment upon the achievement of net sales     $ 20,000,000          
Amount due for New Drug Application     $ 3,000,000          
Scilex Pharma [Member] | Tlido Rest Of World License Agreement [Member]                
Business Acquisition [Line Items]                
Revenue, Remaining Performance Obligation, Percentage 50.00%              
License Agreement                
Business Acquisition [Line Items]                
Development milestones payment was recognized under other long-term liabilities       200,000   200,000 200,000  
License Agreement | Romeg License Agreement [Member]                
Business Acquisition [Line Items]                
Up-front license fee   $ 2,000,000            
Payment upon the achievement of net sales   13,000,000            
Payments for royalties   150,000            
Non-Refundable, Non-Creditable Payment   $ 700,000            
Transfer of Common Stock Shares   22,267            
Intangible asset   $ 5,700,000            
Deferred consideration   $ 3,700,000            
Royalty expenses       $ 200,000 $ 200,000 600,000 300,000  
Contingent consideration, liability           $ 0 $ 0